Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Enabling portable delivery of large-molecule biologics to the lungs

Reference number
Coordinator Kungliga Tekniska Högskolan - KTH Skolan för elektroteknik och datavetenskap
Funding from Vinnova SEK 1 000 000
Project duration September 2023 - June 2024
Status Ongoing
Venture Emerging technology solutions
Call Emerging technology solutions stage 1 2023

Purpose and goal

The purpose of the project is enable pulmonary delivery of large molecule biologic drugs using portable inhalers. Here we aim to demonstrate sucessful in-vivo pulmonary delivery and expression in lung of mRNA therapeutics in a relevant model system using a new spray nozzle technology.

Expected effects and result

We expect to be able to demonstrate uptake of mRNA in lung tissue in living model systems after administration with our new spray nozzle. This would represent an important milestone and enable us to move forward in the commercial process, to form the team and a company, develop the business strategy, and approach potential partners and customers.

Planned approach and implementation

We have already fabricated and tested the Swirl spray nozzles in in-vitro systems. We have demonstrated that sprays does not damage sensitive proteins, LNP or EVs; and we have demonstrated successful delivery of mRNA to cell cultures. We now plan to show proof-of-concept in an appropriate model system. This is a key step taking the technology from its current prototype stage where experimental models have been developed to get first proof-of-concept in vivo. We have planned this work together with Karolinska Institutet Huddinge.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 9 October 2023

Reference number 2023-01345

Page statistics